Vascular complications of diabetes

Editorial

Olga I Stenina. Curr Pharm Des. 2005.

. 2005;11(18):2277-8.

doi: 10.2174/1381612054367319.

No abstract available

Comment on

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.
Yamagishi S, Imaizumi T. Yamagishi S, et al. Curr Pharm Des. 2005;11(18):2279-99. doi: 10.2174/1381612054367300. Curr Pharm Des. 2005. PMID: 16022668 Review.
Microcirculation of the diabetic foot.
Dinh T, Veves A. Dinh T, et al. Curr Pharm Des. 2005;11(18):2301-9. doi: 10.2174/1381612054367328. Curr Pharm Des. 2005. PMID: 16022669 Review.
Novel approaches in the treatment of angiogenic eye disease.
Wegewitz U, Göhring I, Spranger J. Wegewitz U, et al. Curr Pharm Des. 2005;11(18):2311-30. doi: 10.2174/1381612054367292. Curr Pharm Des. 2005. PMID: 16022670 Review.
Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus.
Watala C. Watala C. Curr Pharm Des. 2005;11(18):2331-65. doi: 10.2174/1381612054367337. Curr Pharm Des. 2005. PMID: 16022671 Review.
Regulation of vascular genes by glucose.
Stenina OI. Stenina OI. Curr Pharm Des. 2005;11(18):2367-81. doi: 10.2174/1381612054367283. Curr Pharm Des. 2005. PMID: 16022672 Review.
Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules.
Muro S, Muzykantov VR. Muro S, et al. Curr Pharm Des. 2005;11(18):2383-401. doi: 10.2174/1381612054367274. Curr Pharm Des. 2005. PMID: 16022673 Review.